A. Makedonski 12, 1000 Skopje, Makedonija3Farmatsevtski fakultet-Skopje, Vodnjanska 17, 1000 Skopje,MakedonijaVOVEDHelicobacter pylori e spiralna podvizhna bakterija so flageli.Flagelite i pomagaat efikasno da ja najde tselnata kletka vo zhe-ludnikot. Bakterijata adkherira kon povrshinata na epitelnite153fifth congress of Pharmacy of maceDonia with international ParticiPationMacedonian Pharmaceutical Bulletin 57 (suppl), 2011CLINICAL BIOCHEMISTRY / TOXICOLOGY/ FOOD AND NUTRITION poster presentationskletki. So pomosh na ureazata koja ja produtsira, od ureata koja jaima normalno vo zheludnikot, se osloboduva jaglerod dioksid iamonijak. Oslobodeniot jaglerod dioksid preminuva vo bikarbo-natna forma, koja vrshi neutralizatsija na kiselata pH sredina, soshto bakterijata si go olesnuva svojot opstanok. Proizvedeniotamonijak e toksichen za epitelnite kletki na zheludnikot i zaednoso vakualiziraniot tsitotoksin A (VacA) i nekoi fosfolipazi giunishtuvaat zheludochnite kletki.TsElISo ovaa metoda koja spagja vo neinvazivnite metodi za odreduvanje nainfektsija na H.pylori ispitani se patsienti so gastrichni simptomi(bolki vo stomakot, naduenost, dispepsija, chuvstvo na glad 1-3 chasa poobrok, gadenje) preku istovremeno odreduvanje na IgA i IgG antitelavo serum. Vo ovoj trud e odreden odnosot na kontsentratsijata na IgA iIgG antitela na H.pylori. Ispitano e kolku od patsientite imaatzgolemena vrednost samo na IgA antitela na Helicobacter, kolku odpatsientite imaat zgolemeni vrednosti i na IgA i IgG antitela, a kolkuod patsientite imaat zgolemena kontsentratsija samo na IgG antitela.METODI NA RABOTAPrintsip na ova ispituvanje e ELISA (Enzyme-linked ImmunosorbentAssay) metoda. Toa e kvantitativno imunoenzimsko odreduvanje naIgA i IgG klasi na antitela na H.pylori. Bunarchinjata se oblozheni soantigeni na H.pylori koi se vrzuvaat so sovpagjachkite antitela odprimerotsite. Po perenjeto na bunarchinjata se otstranuva se osvenvrzanite antitela od primerokot, se dodava Horseradish peroxidase(HRP) obelezhan anti-human IgA konjugat. Ovoj konjugat se vrzuva sovekje vrzanite Helicobacter-spetsifichni antitela.Formiraniot imunokompleks se vizuelizira so dodavanje tetrame-tilbenzidin (TMB) supstrat koj dava sin reaktsionen produkt. In-tenzitetot na reaktsioniot produktot e proportsionalen so koli-chinata na Helicobacter-spetsifichni antitela vo primerokot. Zastopiranje na ovaa reaktsija se dodava sulfurna kiselina. So toase dobiva zholta boja, koja e zavrshna tochka na ovaa reaktsija.Apsorbantsata se chita na 450nm, na ELISA chitach.REzUlTATIDobieni se rezultati od izraboteni analizi na antitela na H.pylori- IgA/IgG, kaj 203 patsienti. Dobienata kontsentratsija na IgA antitelae so sredna vrednost 28,13 NTU/ml. Od vkupniot broj na patsienti,88 patsienti se so normalni vrednosti za IgA (< 15 NTU/ml), sosredna vrednost 10,15+-2,99 NTU/ml, 32 patsienti se vo ,,sivata zona"t.e. na granichni vrednosti (15-20 NTU/ml), so sredna vrednost od17,78+-1,49 NTU/ml, a pak 83 patsienti, so zgolemeni vrednosti (>20NTU/ml), so sredna vrednost 51,17 (range 20-246,7) NTU/ml.Izraboteni se analizi od antitela na H.pylori - IgG, kaj 203 patsien-ti, so sredna vrednost 70,61 NTU/ml. Od vkupniot broj na patsienti,53 patsienti se so normalni vrednosti (< 15 NTU/ml), so srednavrednost 8,31+-3,49 NTU/ml, 11 patsienti se vo ,,sivata zona" t.e. nagranichni vrednosti (15-20 NTU/ml), so sredna vrednost od16,76+-1,72 NTU/ml, a pak 139 patsienti, so zgolemeni vrednosti (>20NTU/ml), so sredna vrednost 98,63 (range 20,4-408) NTU/ml.Napraven e tabelaren prikaz na patsienti so razlichen rasporedna kontsentratsii na IgA i IgG antitela. 7,88% od patsientite imaatzgolemena kontsentratsija na IgA, a normalna kontsentratsija na IgGantitela na H.pylori. 32,02% od patsientite imaat zgolemenakontsentratsija na IgA i IgG antitela na H.pylori, a 26,11% od patsien-tite imaat normalna kontsentratsija na IgA, a zgolemena kontsentra-tsija na IgG antitela na H.pylori.zAKlUChOKOd site infitsirani individui, povekje od 90% od patsientiteimaat zgolemena kontsentratsija na IgG antitela, a priblizhno 70%od ovie individui imaat isto taka zgolemeni kontsentratsii na IgAantitela. Samo priblizhno 7% od infitsiranite individui se IgApozitivni, a IgG negativni. Vo nasheto ispituvanje, 69% imaatzgolemeni vrednosti na IgG i 41% zgolemeni vrednosti na IgAantitela na H.pylori. Samo 7,88% imaat zgolemeni vrednosti za IgAantitela, a normalni vrednosti na IgG antitela za H.pylori.Protsentot na zgolemeni vrednosti na IgG i IgA antitelata na H.py-lori kaj patsienti koi ja posetija nashata laboratorija e ponizokbidejkji kaj tie patsienti ne e dijagnostitsirana infektsija na He-licobacter pylori, patsientite se zhalele na simptomi slichni nagastrit. Dokolku kaj patsientite e najdena zgolemena vrednost naantitela - IgA, IgG i/ili IgA/IgG na H.pylori se preporachuva da senapravat popretsizni ispituvanja kako shto e endoskopijata.lITERATURA1. Marshall, B.J, Royce, H, Goodwin, C.S, Taylor, N.S, Edmond, P; Original Isolation ofCampylobacter pyloridis from human gastric mucosa (1982);2. Warren J.R.; Unidentified curved bacilli on gastric epithelium in active chronic gas-tritis (1983);3. Dubois A.; Spiral bacteria in the human stomach: The gastric Helicobacters.(1995);4. Kosunen TU; et al. Diagnostic value of decreasing IgG, IgA, and IgM antibody titersafter eradication of Helicobacter pylori. (1992);5. Van Enk RA. ; Serologic diagnosis of Helicobacter pylori infection. (1996);6. Li S, Lu AP, Zhang L, Li YD; Anti-Helicobacter pylori immunoglobulin G (IgG) and IgAantibody responses and the value of clinical presentations in diagnosis of H. pylori in-fection in patients with precancerous lesions. (2003);cla-containing fooD suPPlementson bulgarian marketAssena Stoimenova, Lili Peykova, Maria Kostova,Stefka Pankova, Kosta Todorov, Lidia Stoycheva,Danka ObreshkovaFaculty of Pharmacy, Medical University, SofiaintroDuctionConjugated linoleic acid (CLA) is a mixture of positional and geometricisomers of linoleic acid in which the double bonds are conjugated. [1] CLAis a common dietary component, with the main sources being beef, lamb,and dairy products. [2] Several physiological effects have been identified,including effects on body composition, serum glucose and insulin,carcinogenesis, cardiovascular variables, bone formation, and immunefunction. [3] The CLA effect on fat loss has been seen in mice, hamsters,rats, chickens, dogs, and pigs. [2,3] There have also been conducted 19randomized, double-blind, placebo-controlled studies in humans that haveyielded varying results. [2] Despite of that, CLA is widely advertised andpromoted for its fat reducing effect. Lots of weight-loss food supplementscontain CLA alone or in combination with other substances.objectivesThe goal of our study is to review the scientific evidence for CLA fat-reducing effect, to investigate the number and content of CLA-con-taining food supplements on the Bulgarian market and to evaluate theinformation available in the leaflets and outer package related tosafety use.154PETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMakedonski farmatsevtski bilten 57 (dodatok), 2011KLINIChKA BIOKhEMIJA / TOKSIKOLOGIJA/ KhRANA I ISKhRANA poster prezentatsiimethoDsCLA-safety information was searched in PubMed, Scopus, Wiley On-line Library, Science Direct, Embase and Internet. The search was per-formed with the following key words: conjugated linoleic acid, bodycomposition, safety and side effects.resultsA total of 11 publications on CLA fat reducing effect and 7 publica-tions related to CLA safety were selected.CLA is often recommended for weight reduction or improving bodycomposition (ratio of muscle to fat) but the evidence from studies isconflicting. [4-12] One meta-analysis concluded that, when taken at adose of 3.2 grams per day, CLA slightly reduces body fat levels. [13] Inone study, a combination of CLA and chromium failed to improve bodycomposition. [14] CLA is believed to be a safe nutritional substance. [15]However, there are some safety concerns with its use. Use of CLA bypeople with diabetes may worsen blood sugar control and in overweightpeople without diabetes, CLA might decrease insulin sensitivity. [10,16,17] Two studies suggested increased cardiovascular risk [18,19]Concerns have also been raised regarding use of CLA by nursingmothers. [20] 13 CLA-containing food supplements are present at theBulgarian market. Only 4 of them are containing CLA only. The rest(69.23 %) are combination products. Most frequent CLA is combinedwith green tea extract, L-carnitin, Pinus koriensis seed oil, caffeine etc.The CLA content varies from 6.2 mg to 800 mg/capsule. The maximumrecommended dosage for two of the products was 3000 mg CLA daily.All products contained strong claims on fast fat-burning effect of CLA.The safety information on use of CLA by nursing women was includedin 10 products (76.92%). Only 2 products contained information relatedto diabetes. One CLA-only product contained information on neces-sary addition of antioxidant in case of long use of CLA.main conclusionsAlthough the scientific data regarding the fat-reducing effect of CLAare contradictory, the information in packaging of CLA-containingfood supplements promises a lot in this respect. Better control andinformation dissemination are needed for safe use.references:Nicolosi RJ, Rogers EJ, Kritchevsky D, Scimeca JA, Huth PJ., Dietary conjugated linoleicacid reduces plasma lipoproteins and early aortic atherosclerosis in hypercholes-terolemic hamsters. Artery. 1997;22(5):266-77Larsen TM, Toubro S, Astrup A. Efficacy and safety of dietary supplements contain-ing conjugated linoleic acid (CLA) for the treatment of obesity-evidence from animaland human studies. J Lipid Res. 2003 Aug 16Belury MA. Dietary conjugated linoleic acid in health: physiological effects and mech-anisms of action. Annu Rev Nutr. 2002;22:505-31West D. Reduced body fat with conjugated linoleic acid feeding in the mouse. FASEBJ. 1997;11:A599.Ferreira M, Kreider R, Wilson M, et al. Effects of conjugated linoleic acid (CLA) sup-plementation during resistance training on body composition and strength [abstract].J Strength Cond Res. 1997;11:280.Blankson H, Stakkestad JA, Fagertun H, et al. Conjugated linoleic acid reduces bodyfat mass in overweight and obese humans. J Nutr. 2000;130:2943-2948.Riserus U, Berglund L, Vessby B. Conjugated linoleic acid (CLA) reduced abdominaladipose tissue in obese middle-aged men with signs of the metabolic syndrome: a ran-domised controlled trial. Int J Obes Relat Metab Disord. 2001;25:1129-1135.Thom E. Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat inhealthy exercising humans. J Int Med Res. 2001;29:392-396.Gaullier JM, Halse J, Hoye K et al. Conjugated linoleic acid supplementation for 1 y re-duces body fat mass in healthy overweight humans. Am J Clin Nutr. 2004;79:1118-1125.Larsen TM, Toubro S, Astrup A. Efficacy and safety of dietary supplements contain-ing conjugated linoleic acid (CLA) for the treatment of obesity-evidence from animaland human studies. J Lipid Res. 2003.Larsen TM, Toubro S, Gudmundsen O, et al. Conjugated linoleic acid supplementationfor 1 y does not prevent weight or body fat regain. Am J Clin Nutr. 2006;83:606-612.Gaullier JM, Halse J, Hoye K, et al. Supplementation with conjugated linoleic acid for24 months is well tolerated by and reduces body fat mass in healthy, overweight hu-mans. J Nutr. 2005;135:778-784.Whigham LD, Watras AC, Schoeller DA. Efficacy of conjugated linoleic acid for re-ducing fat mass: a meta-analysis in humans. Am J Clin Nutr. 2007;85:1203-1211.Diaz ML, Watkins BA, Li Y, et al. Chromium picolinate and conjugated linoleic acid donot synergistically influence diet- and exercise-induced changes in body compositionand health indexes in overweight women. J Nutr Biochem. 2007 May 23.Whigham LD, O'Shea M, Mohede IC, et al. Safety profile of conjugated linoleic acid ina 12-month trial in obese humans. Food Chem Toxicol. 2004;42:1701-1709.Riserus U, Arner P, Brismar K, et al. Treatment with dietary trans10cis12 conjugatedlinoleic acid causes isomer-specific insulin resistance in obese men with the meta-bolic syndrome. Diabetes Care. 2002;25:1516-1521.Moloney F, Yeow TP, Mullen A, et al. Conjugated linoleic acid supplementation, in-sulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus.Am J Clin Nutr. 2004;80:887-895.Taylor JS, Williams SR, Rhys R, et al. Conjugated Linoleic Acid Impairs EndothelialFunction. Arterioscler Thromb Vasc Biol. 2005 Dec 8.Steck SE, Chalecki AM, Miller P, et al. Conjugated linoleic acid supplementation fortwelve weeks increases lean body mass in obese humans. J Nutr.